[ Price : $8.95]
FDA approves an expanded indication for Janssen Biotech''s Remicade (infliximab) for treating moderately to severely active ulcera...[ Price : $8.95]
Attorney John Fleder highlights continuing confusion that exists over FDAs position on off-label drug promotion.[ Price : $8.95]
FDA says that in the second quarter of 2011 it identified potential safety signals in 10 drugs.[ Price : $8.95]
Attorney Arnie Friede says FDA and the courts have made differing interpretations of federal preemption law depending on the drug,...[ Price : $8.95]
FDA clears an Iris International 510(k) for its NADiA ProsVue prognostic cancer test for identifying patients at reduced risk for ...[ Price : $8.95]
FDA places a partial clinical hold on Immunomedics Phase 2B/2 clivatuzumab tetraxetan trial for pancreatic cancer.[ Price : $8.95]
FDA cautions that Primatene Mist will no longer be available as an OTC epinephrine inhaler after 12/31.[ Price : $8.95]
The VA says it will no longer use Avastin to treat wet age-related macular degeneration.